Opus Genetics Inc (IRD) Stock Price, Quote & News

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology

Sector: Healthcare

Phone: 984 884 6030

Website: opusgtx.com

Address:

8 Davis Drive, Suite 220, Durham, United States

alexquick123 Jul. 7 at 3:10 PM

$IRD damn this is like the 100th inducement grant , how about produce revenue first then dish these grants out. Board is already bloated

0 · Reply

Novice1a Jul. 3 at 8:53 PM

$IRD https://ir.opusgtx.com/press-releases/detail/491/opus-genetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4

0 · Reply

Um8a123 Jul. 3 at 3:39 PM

$IRD any day this will rip to 3

1 · Reply

Therhythmofstocks Jul. 2 at 4:27 PM

$IRD she's ripping. Break $1.04 and it's blue skies

0 · Reply

Um8a123 Jul. 2 at 4:16 PM

$IRD Good entry point

0 · Reply

Therhythmofstocks Jul. 1 at 7:45 PM

$IRD this will run more than $MBIO 🚀

0 · Reply

Novice1a Jul. 1 at 7:05 PM

$IRD it's 3:04 pm will they start selling again like the last 2 trading days?

0 · Reply

Therhythmofstocks Jul. 1 at 6:27 PM

$IRD @JL_TradeZ what do you think of the chart? It looked like it's about to pop but I wanted to hear tour opinion

0 · Reply

Um8a123 Jul. 1 at 4:33 PM

$IRD Waiking up, time to run.

0 · Reply

DGains Jul. 1 at 4:08 PM

$NXTT Waking UP!! 🌅 $PMAX Let’s MAX out! 💹 $IRD Soon?! 🔥🛫 $AAPL TOO Easy $$ 💵

0 · Reply

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2025, 6:55 AM EDT - 11 days ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 23, 2025, 8:00 AM EDT - 14 days ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

$Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Jun 2, 2025, 8:00 AM EDT - 5 weeks ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

May 15, 2025, 8:00 AM EDT - 7 weeks ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 6, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 5, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Apr 11, 2025, 3:47 PM EDT - 3 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 8, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Mar 31, 2025, 8:20 AM EDT - 3 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Mar 21, 2025, 5:03 PM EDT - 3 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 9:30 AM EDT - 3 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:11 AM EDT - 3 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 19, 2025, 3:56 PM EDT - 3 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2025, 8:00 AM EST - 4 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Feb 26, 2025, 8:00 AM EST - 4 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 18, 2025, 7:30 AM EST - 4 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 7, 2025, 9:15 AM EST - 5 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Dec 19, 2024, 8:00 AM EST - 7 months ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

alexquick123 Jul. 7 at 3:10 PM

$IRD damn this is like the 100th inducement grant , how about produce revenue first then dish these grants out. Board is already bloated

0 · Reply

Novice1a Jul. 3 at 8:53 PM

$IRD https://ir.opusgtx.com/press-releases/detail/491/opus-genetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4

0 · Reply

Um8a123 Jul. 3 at 3:39 PM

$IRD any day this will rip to 3

1 · Reply

Therhythmofstocks Jul. 2 at 4:27 PM

$IRD she's ripping. Break $1.04 and it's blue skies

0 · Reply

Um8a123 Jul. 2 at 4:16 PM

$IRD Good entry point

0 · Reply

Therhythmofstocks Jul. 1 at 7:45 PM

$IRD this will run more than $MBIO 🚀

0 · Reply

Novice1a Jul. 1 at 7:05 PM

$IRD it's 3:04 pm will they start selling again like the last 2 trading days?

0 · Reply

Therhythmofstocks Jul. 1 at 6:27 PM

$IRD @JL_TradeZ what do you think of the chart? It looked like it's about to pop but I wanted to hear tour opinion

0 · Reply

Um8a123 Jul. 1 at 4:33 PM

$IRD Waiking up, time to run.

0 · Reply

DGains Jul. 1 at 4:08 PM

$NXTT Waking UP!! 🌅 $PMAX Let’s MAX out! 💹 $IRD Soon?! 🔥🛫 $AAPL TOO Easy $$ 💵

0 · Reply

Novice1a Jul. 1 at 12:37 AM

$IRD is this who is dumping their stock or is it locked up?

1 · Reply

JussieLivermore Jun. 30 at 10:33 PM

$IRD Mina the seller? Now that George is recklessly dumping shares on the market and after his pathetic conference call, she is giving up? How do we have a CEO unable to answer simple questions from analyst? Fire the moron.

0 · Reply

JoeD32 Jun. 30 at 9:51 PM

$IRD total profited shares lol

1 · Reply

JoeD32 Jun. 30 at 9:47 PM

$IRD if you’re holding this you’re in for a world of pain 🤣 someone selling shares for 74 cents when it hasnt been there in months 🤣

1 · Reply

Novice1a Jun. 30 at 2:28 PM

$IRD George better be buying all those shares

0 · Reply

MYBE Jun. 30 at 12:02 PM

$IRD Why do some people post a lot here without adding anything new about the stock’s status or any new news?? 🤔 - I think it's okay as long as it trades above 0.90 cents and it will turn positive after exceeding 1.17 dollars...just expectations.👌

0 · Reply

WeekendJerry Jun. 30 at 11:46 AM

$IRD out for now... moving over to $PSTV to play the news from FDA

2 · Reply

WeekendJerry Jun. 30 at 11:25 AM

$IRD why am I in this mofo again? lol

0 · Reply

RCO234 Jun. 29 at 11:32 PM

$IRD From chatgbt

0 · Reply

JussieLivermore Jun. 27 at 9:59 PM

$IRD George has the company selling more shares via the ATM facility.

1 · Reply

WeekendJerry Jun. 27 at 8:21 PM

$IRD facts... usually its the ones where retail has been shaken out so hard and then BOOM it spikes and hardly any retail gets any love....

0 · Reply

WeekendJerry Jun. 27 at 5:18 PM

$IRD wen lambo for kramer?

0 · Reply

Market Cap	59.66M
Revenue (ttm)	10.99M
Net Income (ttm)	-57.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-523.48%
Debt to Equity Ratio	0.00

Volume	217,200
Avg Vol	1,264,286
Day's Range	N/A - N/A
Shares Out	59.66M
Stochastic %K	66%
Beta	-0.02
Analysts	Strong Sell
Price Target	$9.25